Citigroup Maintains Buy on Zymeworks, Raises Price Target to $39

Citigroup analyst Yigal Nochomovitz has reiterated a Buy rating on Zymeworks (NASDAQ: ZYME) and increased the price target from $38 to $39. This adjustment reflects a positive outlook on the company's performance.